These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 2245962)
1. [Why does adequate tolerance of a lipid-lowering agent play such an important role?]. Mutschler E Fortschr Med; 1990; 108 Spec No 1():54-5. PubMed ID: 2245962 [No Abstract] [Full Text] [Related]
3. Lipid-lowering drugs and changes to diet can make a difference. TreatmentUpdate; 2001 Aug; 13(4):7-9. PubMed ID: 11590981 [No Abstract] [Full Text] [Related]
4. [Statines for all or individualized lipid lowering therapy?]. Parhofer K MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849 [No Abstract] [Full Text] [Related]
5. Drugs for lipid disorders. Treat Guidel Med Lett; 2003 Aug; 1(12):77-82. PubMed ID: 15529095 [No Abstract] [Full Text] [Related]
6. [Lipid lowering therapy: new pathophysiologic aspects and clinical implications]. Nordmann A; Martina B; Keller U; Battegay E Schweiz Med Wochenschr; 1998 Apr; 128(17):665-70. PubMed ID: 9622839 [TBL] [Abstract][Full Text] [Related]
7. Summary of present data from a clinical trial of CI-719. Wilkening J; Schwandt P Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):90-3. PubMed ID: 1019158 [No Abstract] [Full Text] [Related]
10. [Effect of tiadenol in prolonged therapy of hyperlipoproteinemias (type IIa-IIb)]. Rouffy J Therapie; 1975; 30(6):815-23. PubMed ID: 785682 [No Abstract] [Full Text] [Related]
11. [Practice guidelines--disorders of lipid metabolism. From recommendations to therapy of disorders of lipid metabolism by the Drug Committee of the German Medical Society. Drug Committee of the German Medical Society]. Z Arztl Fortbild Qualitatssich; 2000 Jan; 94(1):61-4. PubMed ID: 10721166 [No Abstract] [Full Text] [Related]
13. Improvement in current approaches to lipid lowering. Ansell BJ Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952 [No Abstract] [Full Text] [Related]
14. The role of lipid lowering in transplantation. Wierzbicki AS Int J Clin Pract; 1999; 53(1):54-9. PubMed ID: 10344068 [TBL] [Abstract][Full Text] [Related]
15. Common obstacles in lipid management. Elpers M Crit Care Nurs Clin North Am; 2008 Sep; 20(3):287-95. PubMed ID: 18644511 [TBL] [Abstract][Full Text] [Related]
16. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for]. de Teresa Galván E; Jiménez Navarro M Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441 [No Abstract] [Full Text] [Related]
17. A vote of no confidence in the precision of the estimated cost-effectiveness of lipid lowering. Wilcock M Br J Gen Pract; 2000 Nov; 50(460):917-8. PubMed ID: 11141882 [No Abstract] [Full Text] [Related]
18. Niacin for lipid disorders. Indications, effectiveness, and safety. Brown WV Postgrad Med; 1995 Aug; 98(2):185-9, 192-3. PubMed ID: 7630846 [TBL] [Abstract][Full Text] [Related]
20. [Guidelines for lipid-lowering therapy. Results of the 2d Consensus Conference of the European Atherosclerosis Society. Press conference. London, 6 May 1988]. Fortschr Med Suppl; 1988; 46():1-22. PubMed ID: 2905324 [No Abstract] [Full Text] [Related] [Next] [New Search]